NCT06484556View on ClinicalTrials.gov

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

PHASE1RecruitingINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

June 19, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions

Tumor, Solid

Interventions

DRUG

NW-301V

TCR-T cell targeting KRAS G12V mutation

DRUG

NW-301D

TCR-T cell targeting KRAS G12D mutation

Trial Locations (2)

430022

RECRUITING

Wuhan Union Hospital, Wuhan

Unknown

RECRUITING

Wuhan Union Hospital, Wuhan

Sponsors

Collaborators (1)

Neowise Biotechnology

All Listed Sponsors

collaborator

Neowise Biotechnology

INDUSTRY

lead

Tao Zhang

OTHER